WITHUS PHARMACEUTICALLTD Balance Sheet Health
Financial Health criteria checks 4/6
WITHUS PHARMACEUTICALLTD has a total shareholder equity of ₩90.7B and total debt of ₩21.0B, which brings its debt-to-equity ratio to 23.2%. Its total assets and total liabilities are ₩130.5B and ₩39.8B respectively. WITHUS PHARMACEUTICALLTD's EBIT is ₩8.6B making its interest coverage ratio 43.3. It has cash and short-term investments of ₩8.7B.
Key information
23.2%
Debt to equity ratio
₩21.02b
Debt
| Interest coverage ratio | 43.3x |
| Cash | ₩8.65b |
| Equity | ₩90.72b |
| Total liabilities | ₩39.76b |
| Total assets | ₩130.48b |
Recent financial health updates
Recent updates
These 4 Measures Indicate That WITHUS PHARMACEUTICALLTD (KOSDAQ:330350) Is Using Debt Reasonably Well
Nov 13
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings
May 25Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like
Feb 17Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)
Jan 13
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Financial Position Analysis
Short Term Liabilities: A330350's short term assets (₩57.3B) exceed its short term liabilities (₩31.8B).
Long Term Liabilities: A330350's short term assets (₩57.3B) exceed its long term liabilities (₩7.9B).
Debt to Equity History and Analysis
Debt Level: A330350's net debt to equity ratio (13.6%) is considered satisfactory.
Reducing Debt: A330350's debt to equity ratio has increased from 21.4% to 23.2% over the past 5 years.
Debt Coverage: A330350's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: A330350's interest payments on its debt are well covered by EBIT (43.3x coverage).